Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00848718 | A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | completed | Phase 1 | 77 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 12, 2019 | clinicaltrials |
| NCT02553499 | Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) | terminated | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 4, 2019 |
| NCT00140894 | A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) | terminated | Phase 4 | 62 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 20, 2019 | clinicaltrials |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) | terminated | Phase 2 / Phase 3 | 344 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
| NCT03065023 | Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) | terminated | Phase 1 / Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | terminated | Phase 2 / Phase 3 | 126 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 24, 2019 | clinicaltrials |
| NCT03554005 | Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009) | completed | Phase 1 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 15, 2019 | clinicaltrials |
| NCT03099161 | Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jun 5, 2019 | clinicaltrials |
| NCT00874731 | A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037) | completed | Phase 1 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 6, 2019 | clinicaltrials |
| NCT01380184 | Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) | completed | Phase 1 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 19, 2019 | clinicaltrials |
| NCT00670488 | Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) | completed | Phase 1 | 104 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2019 | clinicaltrials |
| NCT01605396 | A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 25, 2019 | clinicaltrials |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Mar 25, 2019 | clinicaltrials |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | terminated | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 15, 2019 | clinicaltrials |
| NCT01431534 | A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) | terminated | Phase 1 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 1, 2019 | clinicaltrials |
| NCT00836927 | Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) | terminated | Phase 2 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 18, 2019 | clinicaltrials |
| NCT00834106 | Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) | completed | Phase 3 | 3,006 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2019 | clinicaltrials |
| NCT02731742 | Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001) | terminated | Phase 1 | 14 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2019 | clinicaltrials |
| NCT00988884 | A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) | completed | Phase 3 | 1,241 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 14, 2018 | clinicaltrials |
| NCT01254643 | A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | completed | Phase 3 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 28, 2018 | clinicaltrials |
| NCT01544478 | V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) | completed | Phase 4 | 1,030 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 28, 2018 | clinicaltrials |
| NCT00543543 | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) | completed | Phase 3 | 14,840 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01047345 | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | completed | Phase 3 | 924 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01073293 | A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) | completed | Phase 3 | 1,054 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01651949 | Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) | completed | Phase 3 | 2,520 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01245764 | GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) | completed | Phase 3 | 250 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 14, 2018 | clinicaltrials |
| NCT02114385 | A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) | completed | Phase 3 | 500 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Nov 1, 2018 | clinicaltrials |
| NCT00635778 | A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) | completed | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 9, 2018 | clinicaltrials |
| NCT00779584 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | completed | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT00907517 | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) | terminated | Phase 1 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01451437 | Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) | terminated | Phase 1 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01463696 | Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) | terminated | Phase 1 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT00551213 | A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | completed | Phase 2 | 67 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 24, 2018 | clinicaltrials |
| NCT00954512 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | terminated | Phase 1 / Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 24, 2018 | clinicaltrials |
| NCT00090285 | An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) | completed | Phase 3 | 4,065 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | terminated | Phase 2 | 219 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT02155322 | A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) | completed | Phase 2 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT00399802 | A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) | completed | Phase 2 | 43 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 16, 2018 | clinicaltrials |
| NCT01243762 | A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) | terminated | Phase 1 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 16, 2018 | clinicaltrials |
| NCT00759785 | A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) | completed | Phase 1 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2018 | clinicaltrials |
| NCT00925015 | Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) | completed | Phase 1 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2018 | clinicaltrials |
| NCT00614393 | Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | completed | Phase 2 | 558 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT00654420 | A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT00694356 | Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) | completed | Phase 1 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01636960 | A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials